|
|
|
| Expression and clinical significance of serum miR-29a and miR-143-3p in patients with polycystic ovary syndrome |
| FANG Xiuli1 WANG Daying1 HUANG Xiumin1 CHAO Pengli2 SHE Jingrong3 WEI Zhuohua3 |
1.Department of Obstetrics and Gynecology, Zhongshan Hospital Affiliated to Xiamen University, Fujian Province, Xiamen 361004, China;
2.Department of Clinical Laboratory, Zhongshan Hospital Affiliated to Xiamen University, Fujian Province, Xiamen 361004, China;
3.Department of Clinical Medicine, Xiamen University Medical School, Fujian Province, Xiamen 361004, China |
|
|
|
|
Abstract Objective To analyze the relationship between serum microRNA (miRNA)-29a and miR-143-3p expression and obesity, glucolipid metabolism, and insulin resistance (IR) in patients with polycystic ovary syndrome (PCOS). Methods A total of 86 patients with PCOS admitted to Zhongshan Hospital Affiliated to Xiamen University (hereinafter referred to as “our hospital”) from June 2019 to June 2022 were selected as the PCOS group, and 49 healthy volunteers with physical examination in our hospital during the same period were selected as the control group. PCOS patients were divided into the obese group (36 cases) and the non-obese group(50 cases) according to body mass index (BMI), and they were divided into the IR group (61 cases) and the non-IR group (25 cases) according to homeostasis model assessment (HOMA)-IR. Serum miR-29a, miR-143-3p expression and obesity indicators (BMI, waist-to-hip ratio [WHR]), glucolipid metabolism indicators (fasting blood glucose [FBG], fasting insulin [FINS], total cholesterol [TC], triacylglycerol [TG], high-density lipoprotein cholesterol [HDL-C], and low-density lipoprotein cholesterol [LDL-C]) and HOMA-IR of all groups were compared; the correlation between serum miR-29a and miR-143-3p expression and obesity indicators, glucolipid metabolism indicators, and HOMA-IR in PCOS patients were analyzed. Results BMI, WHR, FBG, FINS, HOMA-IR, TC, TG, LDL-C, miR-29a, and miR-143-3p in PCOS group were higher than those in control group, and HDL-C was lower than that in the control group (P＜0.05). Serum miR-29a and miR-143-3p expression in the obese group were higher than those in the non-obese group (P＜0.05). Serum miR-29a and miR-143-3p expression in the IR group were higher than those in the non-IR group (P＜0.05). Serum miR-29a and miR-143-3p expression in PCOS patients were positively correlated with BMI, WHR, FBG, FINS, HOMA-IR, TC, TG, and LDL-C (r/rs＞0, P＜0.001) and HDL-C was negatively correlated (r＜0, P＜0.001). Conclusion High expression of serum miR-29a and miR-143-3p in PCOS patients is closely associated with obesity, glucose and lipid metabolism, and IR.
|
|
|
|
|
|
[1] 中国医师协会内分泌代谢科医师分会.多囊卵巢综合征诊治内分泌专家共识[J].中华内分泌代谢杂志，2018，34（1）：1-7.
[2] 多囊卵巢综合征相关不孕治疗及生育保护共识专家组，中华预防医学会生育力保护分会生殖内分泌生育保护学组.多囊卵巢综合征相关不孕治疗及生育保护共识[J].生殖医学杂志，2020，29（7）：843-851.
[3] Guan C，Zahid S，Minhas AS，et al. Polycystic ovary syndrome：a “risk-enhancing” factor for cardiovascular disease [J]. Fertil Steril，2022，117（5）：924-935.
[4] 郑小莉，刘永利，张秀智.改良阿特金斯饮食对超重/肥胖多囊卵巢综合征患者糖脂代谢、体成分、性激素水平及月经影响[J].中国计划生育学杂志，2022，30（3）：582- 586，591.
[5] 朱万龙，刘鑫，李梦雅，等.降血糖药物治疗多囊卵巢综合征的研究进展[J].医药导报，2022，41（8）：1157-1163.
[6] 杨东霞，申儒霞，李红梅，等.微小RNA在多囊卵巢综合征发病机制中的研究进展[J].中国生育健康杂志，2022， 33（1）：81-83，89.
[7] Chakraborty C，Doss CG，Bandyopadhyay S，et al. Influence of miRNA in insulin signaling pathway and insulin resistance：micro-molecules with a major role in type-2 diabetes [J]. Wiley Interdiscip Rev RNA，2014，5（5）：697-712.
[8] Tian-Min Y，Suxia L，Shufang D，et al. Combined transcriptomic and metabolomic analysis of women with polycystic ovary syndrome [J]. Dis Markers，2022，8（2022）：4000424.
[9] 中华医学会妇产科学分会内分泌学组及指南专家组.多囊卵巢综合征中国诊疗指南[J].中华妇产科杂志，2018， 53（1）：2-6.
[10] Matthews DR，Hosker JP，Rudenski AS，et al. Homeostasis model assessment：insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man [J]. Diabetologia，1985，28（7）：412-419.
[11] 中华人民共和国卫生部疾病控制司.中国成人超重和肥胖症预防控制指南[R].北京：人民卫生出版社，2006.
[12] 中华医学会糖尿病学分会胰岛素抵抗学组（筹）.胰岛素抵抗评估方法和应用的专家指导意见[J].中华糖尿病杂志，2018，10（6）：377-385.
[13] 孙桂丽，赵冉冉.基于代谢组学的多囊卵巢综合征研究进展[J].中华内分泌代谢杂志，2022，38（6）：534-538.
[14] Yang R，Li Q，Zhou Z，et al. Changes in the prevalence of polycystic ovary syndrome in China over the past decade [J]. Lancet Reg Health West Pac，2022，5（25）：100494.
[15] 乔杰，李蓉，李莉，等.多囊卵巢综合征流行病学研究[J].中国实用妇科与产科杂志，2013，29（11）：849-852.
[16] 吴亚妹，马宁，黄兹宝，等.胰岛素抵抗影响多囊卵巢综合征发病及机制的研究进展[J].生殖医学杂志，2021， 30（9）：1247-1251.
[17] Sadeghi HM，Adeli I，Calina D，et al. Polycystic ovary syndrome：a comprehensive review of pathogenesis，management，and drug repurposing [J]. Int J Mol Sci，2022，23（2）：583.
[18] Berni TR，Morgan CL，Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events：a population study [J]. J Clin Endocrinol Metab，2021，106（9）：e3369-e3380.
[19] Sun Y，Zhou Y，Shi Y，et al. Expression of miRNA-29 in Pancreatic β Cells Promotes Inflammation and Diabetes via TRAF3 [J]. Cell Rep，2021，34（1）：108576.
[20] Wu P，Wang Q，Jiang C，et al. MicroRNA-29a is involved lipid metabolism dysfunction and insulin resistance in C2C12 myotubes by targeting PPARδ[J]. Mol Med Rep，2018，17（6）：8493-8501.
[21] Liu T，Sun YC，Cheng P，et al. Adipose tissue macrophage-derived exosomal miR-29a regulates obesity-associated insulin resistance [J]. Biochem Biophys Res Commun，2019， 515（2）：352-358.
[22] Lin X，Du Y，Lu W，et al. CircRNF111 Protects Against Insulin Resistance and Lipid Deposition via Regulating miR-143-3p/IGF2R Axis in Metabolic Syndrome [J]. Front Cell Dev Biol，2021，8（9）：663148.
[23] Lin XH，Tang SJ，Gui WW，et al. Circulating miR-143-3p inhibition protects against insulin resistance in Metabolic Syndrome via targeting of the insulin-like growth factor 2 receptor [J]. Transl Res，2019，5（205）：33-43.
[24] 段广靖，谢锋，王斌，等.过氧化物酶体增值物激活受体α在代谢性疾病中的研究进展[J].海南医学院学报，2021，27（22）：1754-1760.
[25] Kaur S，Archer KJ，Devi MG，et al. Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance：identification of susceptibility gene sets through network analysis [J]. J Clin Endocrinol Metab，2012，97（10）：E2016-E2021. |
|
|
|
